130 related articles for article (PubMed ID: 30930224)
1. Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Cai MJ; Cui Y; Fang M; Wang Q; Zhang AJ; Kuai JH; Pang F; Cui XD
Gene; 2019 Jun; 702():66-74. PubMed ID: 30930224
[TBL] [Abstract][Full Text] [Related]
2. PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibition.
Zhang J; Fang S; Rong F; Jia M; Wang Y; Cui H; Hao P
Hum Cell; 2023 Sep; 36(5):1755-1772. PubMed ID: 37336868
[TBL] [Abstract][Full Text] [Related]
3. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1α Pathway.
Zhang X; Han K; Yuan DH; Meng CY
DNA Cell Biol; 2017 Apr; 36(4):256-263. PubMed ID: 28191864
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
7. IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation.
Lei T; Ling X
World J Gastroenterol; 2015 Sep; 21(35):10137-49. PubMed ID: 26401078
[TBL] [Abstract][Full Text] [Related]
8. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma.
Zhang X; Lin C; Song J; Chen H; Chen X; Ren L; Zhou Z; Pan J; Yang Z; Bao W; Ke X; Yang J; Liang Y; Huang H; Tang D; Jiang L; Liu J
Cell Death Dis; 2019 Sep; 10(10):719. PubMed ID: 31558697
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB.
Fang L; Sun J; Pan Z; Song Y; Zhong L; Zhang Y; Liu Y; Zheng X; Huang P
Am J Physiol Gastrointest Liver Physiol; 2017 Aug; 313(2):G150-G156. PubMed ID: 28526689
[TBL] [Abstract][Full Text] [Related]
10. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
11. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).
Zhu Q; Gong L; Wang J; Tu Q; Yao L; Zhang JR; Han XJ; Zhu SJ; Wang SM; Li YH; Zhang W
BMC Cancer; 2016 Oct; 16(1):806. PubMed ID: 27756250
[TBL] [Abstract][Full Text] [Related]
12. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
13. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
14. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence.
Xia H; Kong SN; Chen J; Shi M; Sekar K; Seshachalam VP; Rajasekaran M; Goh BKP; Ooi LL; Hui KM
Cancer Lett; 2016 Dec; 383(1):85-93. PubMed ID: 27693640
[TBL] [Abstract][Full Text] [Related]
15. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
16. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Wang W; Jia WD; Hu B; Pan YY
Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
Wu YX; Yang JH; Saitsu H
Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
[TBL] [Abstract][Full Text] [Related]
18. Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells.
Liu T; Yu X; Li G; Yuan R; Wang Q; Tang P; Wu L; Liu X; Peng X; Shao J
Exp Cell Res; 2012 Oct; 318(16):1994-2003. PubMed ID: 22705122
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of S-phase kinase-associated protein 2-mediated p27 degradation suppresses tumorigenesis and the progression of hepatocellular carcinoma.
Qi M; Liu D; Zhang S; Hu P; Sang T
Mol Med Rep; 2015 May; 11(5):3934-40. PubMed ID: 25572801
[TBL] [Abstract][Full Text] [Related]
20. BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.
Bai Y; Wang J; Han J; Xie XL; Ji CG; Yin J; Chen L; Wang CK; Jiang XY; Qi W; Jiang HQ
Mol Carcinog; 2017 Mar; 56(3):1137-1149. PubMed ID: 27770580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
